Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa
about
Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized TrialsHarnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosisFunctional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosisIncidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysisData needs for evidence-based decisions: a tuberculosis modeler's 'wish list'Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus loadPersistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challengeAntiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methodsScreening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective studyUse of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic reviewIncidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, BrazilEarly versus Delayed Antiretroviral Therapy for HIV and Tuberculosis Co-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsExpanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050HIV and Tuberculosis: a Deadly Human SyndemicImpact of human immunodeficiency virus and CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South Africa.CD4-CD8-αβ and γδ T cells display inflammatory and regulatory potentials during human tuberculosis.HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria.Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan AfricaShort and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in SenegalLow haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort studyHighly active antiretroviral treatment for the prevention of HIV transmission.Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India.Serological diagnostic assays for HIV-associated tuberculosis in sub-Saharan Africa?Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV--Kenya, 1998-2012Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?Outcome of tuberculosis treatment and its predictors among HIV infected patients in southwest Ethiopia.Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count.HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis?Changing concepts of "latent tuberculosis infection" in patients living with HIV infection.The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township.Antiretroviral therapy for tuberculosis control in nine African countries.Variation of Mycobacterium tuberculosis antigen-specific IFN-γ and IL-17 responses in healthy tuberculin skin test (TST)-positive human subjects.Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART.Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART.Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as preventionIncidence and determinants of tuberculosis among adults initiating antiretroviral therapy--Mozambique, 2004-2008.
P2860
Q26778385-415126A2-9AEA-40A9-AAFB-C86ACD304661Q26828443-DC3ECAE7-3827-4E11-AB5E-77F67BD3F0E8Q26849399-8EF0004A-07AE-4E91-A6B9-2C8A2689708EQ27012753-9690BCC9-AFFD-4D17-8708-156CD2A3E152Q27015848-5BFB36CF-D8C4-49D2-8516-EBD29965B503Q27333218-9B2FF897-94A2-4EC0-9E83-6B6ED55A6654Q28088557-0238375A-88BB-4F5A-B7D0-999FD5D052F7Q28478065-F669459C-2D7B-4A81-8EC8-5C69BED69980Q28479309-31ED5C0C-31B5-4DEE-BB89-BB3ADD0685FEQ28484857-6CDE57AE-3273-47C2-93D2-D425FB5E80E4Q28487920-83A017E1-9D06-4AE3-B302-6AEF92AFAEB1Q28547436-F40EEB91-5B77-4C02-B574-37673782FF5FQ28732123-2A7A41C0-C1AA-474C-A022-A34082D5E2BCQ30052157-BE1249B7-C452-434E-9F4C-21E304F7650EQ30653441-F500EF88-3657-4CD3-8948-BC8035DE844FQ31109167-8898FF3E-CD67-4002-8082-701769971DC3Q33551482-F95A4BF8-D79A-44E4-96A3-8A6509457030Q33580153-771D64EB-D53D-4BC6-9C63-3DD9E593C94AQ33616426-4AD21639-0B32-445C-BC8C-E419757CB6B7Q33638969-D7F098FD-F6FB-4FD2-9411-5990BDF2D9B9Q33657373-A8E5D7A1-7653-4F3B-8234-86806936B0F9Q33700455-205C643E-E71E-46CD-9B44-C049DD0A90EDQ33743476-FACF88FA-2C64-4D66-A9BE-093F7B25D93FQ33768889-0CF339C1-1BA9-4B67-BF8D-28DD500CB61CQ33795967-62C90537-4A60-45CB-AC6D-5DDC9A4FEA87Q33806776-3CD877D5-4592-4819-BA4C-31519C4F2738Q33920318-A82D327C-126D-421A-9988-AA97D26CAE60Q34056936-3F8DE6C7-8E2F-49DB-8353-3EF2958A743DQ34159662-9C1C22E2-1330-469D-A619-E987AD038A65Q34170017-8DC55A9E-3AA4-4E9F-BF85-E96BE350D1E9Q34193050-A9BE2EA7-B336-4ACB-85BD-9C21F9250052Q34222186-8E83DDA3-FC9D-4F0B-8A8F-5490A1D39053Q34268952-B5021ACD-34F0-4061-AA6A-01F6E2BF70E9Q34320245-6B1E0A08-CC83-42A7-A24F-B7F565C258E9Q34374644-87C77FA0-F6C6-4448-ADB2-34379CB4A89CQ34387168-EDB1632D-517B-489A-9FE2-CE2AA00EEECAQ34416963-CCBF1075-7F27-4652-A77F-A70002B70692Q34438327-62BA2659-8336-45A2-882F-3F85A93204E7Q34519553-B1FD3F45-78D2-4AF1-B522-E78193D67F5CQ34563388-7C58837C-A65B-4C76-A06E-C8C886695EB8
P2860
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Short-term and long-term risk ...... oviral therapy in South Africa
@en
Short-term and long-term risk ...... viral therapy in South Africa.
@nl
type
label
Short-term and long-term risk ...... oviral therapy in South Africa
@en
Short-term and long-term risk ...... viral therapy in South Africa.
@nl
prefLabel
Short-term and long-term risk ...... oviral therapy in South Africa
@en
Short-term and long-term risk ...... viral therapy in South Africa.
@nl
P2860
P50
P921
P1433
P1476
Short-term and long-term risk ...... oviral therapy in South Africa
@en
P2093
David Edwards
P2860
P304
P356
10.1097/QAD.0B013E32832D3B6D
P407
P577
2009-08-01T00:00:00Z